ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,064.20
      0.91%
      US Tech 100
      17,173.20
      1.85%
      Dow Jones
      38,225.66
      0.85%
      Brent Oil
      83.715
      0.10%
      Bitcoin
      59,727.01
      1.02%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Kodiak Sciences Inc (KOD)

      7. Kodiak Sciences Inc (KOD) News

      KOD

      Kodiak Sciences (KOD)

      Kodiak Sciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KOD
      DateTimeSourceHeadlineSymbolCompany
      2:07PMiHub NewswireFeaturedNanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
      05/02/20244:30PMPR Newswire (US)Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformNASDAQ:KODKodiak Sciences Inc
      03/28/20246:30AMPR Newswire (US)Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KODKodiak Sciences Inc
      03/26/20246:15AMPR Newswire (US)Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024NASDAQ:KODKodiak Sciences Inc
      02/14/20244:23PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KODKodiak Sciences Inc
      01/30/20246:30AMPR Newswire (US)Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual MeetingNASDAQ:KODKodiak Sciences Inc
      01/04/20244:15PMPR Newswire (US)Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KODKodiak Sciences Inc
      11/21/20234:15PMPR Newswire (US)Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KODKodiak Sciences Inc
      11/14/20234:01PMPR Newswire (US)Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:KODKodiak Sciences Inc
      11/06/20236:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KODKodiak Sciences Inc
      11/06/20235:00AMPR Newswire (US)Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submissionNASDAQ:KODKodiak Sciences Inc
      11/01/202311:21PMPR Newswire (US)KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETINGNASDAQ:KODKodiak Sciences Inc
      10/11/20236:00AMPR Newswire (US)Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina SocietyNASDAQ:KODKodiak Sciences Inc
      09/08/20236:00AMPR Newswire (US)Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:KODKodiak Sciences Inc
      09/07/20236:00AMPR Newswire (US)New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusionNASDAQ:KODKodiak Sciences Inc
      08/17/20235:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KODKodiak Sciences Inc
      08/14/20234:33PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KODKodiak Sciences Inc
      08/14/20234:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KODKodiak Sciences Inc
      08/14/20234:01PMPR Newswire (US)Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:KODKodiak Sciences Inc
      07/24/20236:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KODKodiak Sciences Inc
      07/24/20236:00AMPR Newswire (US)Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development ProgramNASDAQ:KODKodiak Sciences Inc
      07/03/20234:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KODKodiak Sciences Inc
      07/03/20234:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KODKodiak Sciences Inc
      06/27/20235:36PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
      06/27/20235:33PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
      06/27/20235:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
      06/13/20235:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
      06/13/20235:31PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KODKodiak Sciences Inc
      06/07/20234:02PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KODKodiak Sciences Inc
      06/05/20236:07AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KODKodiak Sciences Inc
       Showing the most relevant articles for your search:NASDAQ:KOD